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tionmedications are due to the availability of a variety of antipsychotics which are
widely used for both acute schizophrenia and as maintenance medications. This
cost estimate may help health care providers and policymakers better understand
the economic burden of schizophrenia and identify services associated with the
highest costs.
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INDIRECT COSTS (IC) OF ADULT WOMEN WITH ANXIETY DISORDERS (AD) IN
THE UNITED STATES IN 2006 FROM THE MEDICAL EXPENDITURES PANEL
SURVEY (MEPS)
Kavati A, Rappaport H
University of Louisiana at Monroe, Monroe, LA, USA
OBJECTIVES: To estimate the IC for adult women with AD in the United States in
2006. METHODS: Females  17 years who reported AD were selected. A control
group was created using propensity score matching.The components of indirect
costs were annual national cost of missed work days for employed individuals,
annual national cost of other bed days for unemployed individuals, and the present
value of future productivity due to premature deaths. To calculate the number of
missedwork days attributable to AD, the unadjustedmean number ofmissedwork
days and other bed days for those without AD was multiplied by the regression
coefficient for AD from the multivariate regression minus the unadjusted mean
number of missed work days and other bed days for those without AD. Using the
number days attributable to AD and the MEPS sample weights for each individual,
the total cost of missed work days and other bed days attributable to AD in the
United States was estimated. Mortality costs were calculated as the present value
of future productivity due to premature deaths. The total amount of indirect costs
was estimated by adding the total from morbidity estimate to the total from the
mortality estimate. RESULTS: The morbidity costs was $8.13 billion and mortality
costs was $0.46 billion. CONCLUSIONS: Morbidity costs due to lost productivity
were the major costs of IC and indicate a significant financial burden that can be
reduced by disease management programs.
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TRAJECTORY ANALYSIS OF HEALTH CARE COSTS FOR PATIENTS WITH MAJOR
DEPRESSIVE DISORDER TREATED WITH HIGH DOSES OF DULOXETINE
Cui Z, Faries D, Zhao Y, Niu L, Novick D, Liu X
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: To examine healthcare cost patterns prior to and following dulox-
etine initiation in patients with major depressive disorder (MDD), focusing on pa-
tients whose dose was initially high or was titrated to high levels.METHODS: This
was a retrospective analysis of 10,987 patients aged 18 to 64 years treated in a
real-world clinical setting and enrolled in health insurance for the 6 months pre-
ceding and 12 months following initiation of duloxetine. Repeated measures and
pre-post analyses were used to examine longitudinal healthcare cost trajectories
before and after initiation of low- (60 mg/day), standard- (60 mg/day), and high-
(60mg/day) dose duloxetine. Classification and regression tree analysis was used
to identify factors influencing patient heterogeneity in healthcare cost outcomes
for patients whose doses were titrated to high levels. RESULTS: Low, standard, and
high doses of duloxetine were initiated for 29.6%, 60.9%, and 9.5% of patients,
respectively, with 13.7% received titrated high dose within 6 months duloxetine
initiation. Regardless of dose, total costs increased in the months leading to and
decreased in the months following initiation of treatment. Patients whose dose
was initially60 mg/day had higher costs both prior to and throughout the course
of treatment as compared to patients treated with standard-dose duloxetine. Fol-
lowing dose escalation to 60 mg/day, costs were higher for medication but lower
for inpatient services, resulting in total cost neutrality. Titration to high-dose ther-
apy was cost beneficial for patients with histories of a mental disorder and high
prior medical costs. CONCLUSIONS: Patients with MDD had cost increases leading
to and cost declines following initiation of duloxetine therapy. Patients treated
with60mg/day had higher healthcare costs both prior to and following initiation
compared to those treated with 60 mg/day. Increases in pharmacy costs associ-
ated with escalation to high-dose therapy were offset by reduced inpatient costs.
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OBJECTIVES:To compare real-world healthcare costs after initiation of second-line
antidepressant treatment with duloxetine vs. generic selective serotonin reuptake
inhibitors (SSRIs) for major depressive disorder (MDD). METHODS: Study sample
was selected from a de-identified U.S. privately-insured claims database (2005-
2009). Selection criteria: age 18-64 years,1MDDdiagnosis (ICD-9-CM: 296.2, 296.3)
in an inpatient setting or 2 MDD diagnoses in emergency room/outpatient set-
tings, initiation of an antidepressant treatment after a 3-monthwashout, initiation
of a second-line treatment with duloxetine or generic SSRI (defined as the index
date) no later than 90 days after the end of first-line treatment, continuous cover-
age eligibility from 6 months before the index date (baseline period) to 12 months
after the index date (study period). Using optimal matching on propensity scores
and baseline costs, 838 patients initiating second-line duloxetine were matched to
838 patients initiating second-line generic SSRI. McNemar tests were used to com-
pare proportions. Bias-corrected bootstrapping was used to compare healthcare
costs (reimbursement to providers for medical services and prescription drugs)
inflated to 2009 dollars. RESULTS: Before matching, second-line duloxetine com-
paredwith generic SSRI userswere older,more likely to be female, had ahigher rate
of chronic pain, and had higher baseline prescription drug costs and $2,967 higher
study period healthcare costs. Aftermatching, therewere no notable differences in
baseline characteristics and costs. Aftermatching, neither study period healthcare
costs ($11,342 vs. $10,328, p.2316) nor medical costs ($8,377 vs. $8,051 p.7063)
were significantly different between second-line duloxetine and generic SSRI us-
ers. Prescription drug costs were significantly higher for second-line duloxetine
users ($2,965 vs. $2,277, p.0001), largely due to differences in mental health-re-
lated drug costs ($1,605 vs. $1,008, p.0001).CONCLUSIONS:Controlling for patient
differences, this study found that second-line duloxetine users had similarmedical
costs and higher drug costs compared with second-line generic SSRI users.
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THE EFFECTIVENESS OF BUPRENORPHINE-MEDICATION ASSISTED TREATMENT
AMONG AETNA’S OPIOID DEPENDENT MEMBERS: AN ANALYSIS OF HEALTH
CARE COSTS AND SERVICE UTILIZATION
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OBJECTIVES: Buprenorphine-medication assisted treatment (B-MAT) is an effec-
tive treatment for opioid dependence (OD), but may be considered cost-prohibitive
by patients and health plans who manage its use based on ingredient cost alone.
This analysis was conducted to estimate economic costs and benefits of B-MAT for
OD from the perspective of a health plan sponsor.METHODS: A longitudinal, mul-
tivariate analysis was conducted using service use claims data among a sample of
Aetnamembers with full benefit coverage and one ormore diagnoses of OD during
the 48 monthmeasurement period (Q1 2006 to Q4 2009). ODmembers treated with
B-MAT (n  725) were compared to members not treated with B-MAT (n  1410).
Two six-month measurement periods were constructed around the index date: a
sixmonth pre-period and a sixmonth post-period.RESULTS:During the six-month
post period, B-MATmembers filled an average of 0.29 (P 0.001)more prescriptions
and had an average of 0.21 more psychiatrist visits (P 0.001) than non B-MAT
members, but utilized significantly fewer behavioral health inpatient hospital ad-
missions (0.82), behavioral health hospital days (0.71), medical inpatient hospi-
tal days (0.39), and emergency room visits (0.31; P’s 0.001). Concerning health-
care costs, B-MATmembers spent $5305 less on inpatient hospital costs (P0.002),
$542 less on emergency room costs (P 0.016), and $6,378 less on total health care
costs per member compared to non B-MAT members (P 0.001). CONCLUSIONS:
Though B-MAT patients incur higher pharmacy costs, they use fewer expensive
health care services in other areas, resulting in an overall positive cost-benefit.
Assuming present results remain in direction and magnitude across other health
plans, and from year to year, health plans can experience considerable savings
using B-MAT as a first line of treatment for OD supported by outpatient services
such as office based providers and counselors.
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MEASURING THE IMPACT OF PERSISTENCE WITH PSYCHOTROPIC DRUG
THERAPY ON TREATMENT COSTS FOR PATIENTS WITH SCHIZOPHRENIA
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OBJECTIVES: To investigate the relationship between persistence with drug ther-
apy and treatment costs in patients with schizophrenia. METHODS: Paid claims
data from a commercial insurer was used to identify patients with schizophrenia.
The unit of observation was the drug treatment episode. A total of 21,570 episodes
were included in ordinary least squares (OLS) regressionmodels of post-treatment
cost as a function of alternative definitions of compliance adjusting for patient
demographics, drug use history, prior medical care use, schizophrenia diagnosis
and co-morbid medical conditions. RESULTS: Adding a second medication within
one year is the key factor in this study. When compared to patients achieving one
year of continuous therapy on the initial drug without switch or augment on a
second drug; patients completing one year of therapy on their initial drug while
adding an augmenting medication experienced increased drug costs by $1,565
(p0.0001) and increased medical costs of $6,583(p0.0001). Patients who did not
achieve compliance on their initial medication, but did achieve compliance on
their second medication exhibit higher total costs $11,381(p0.0001). Patients us-
ing less than one year of psychotropicmedication despite switching to or augment-
ing with a second drug experienced reduced drug costs, but also experienced in-
creased medical costs. Similarly, patients who discontinued their initial therapy
within one year but restart therapy using these medications also experienced re-
duced drug costs and increased medical costs. Finally, patients who quit their
initial and any other therapy within one year save drug costs but also experience
significantly higher medical costs. CONCLUSIONS: Compliance is associated with
significant reductions in medical costs only if the initial drug regimen is main-
tained for 12 months. On the other hand, patients using less than one year of
psychotropicmedication experienced reduced drug costs relative to themost com-
pliant patients(the comparison group), but also experienced increased medical
costs.
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AND COSTS FOLLOWING THE INITIATION OF ORAL VERSUS LONG-ACTING
INJECTABLE RISPERIDONE IN PATIENTS WITH SCHIZOPHRENIA
Park H, Kim DN, Rascati KL
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OBJECTIVES: To assess the patterns of mental-health related medical care utiliza-
tion and medical costs in patients with schizophrenia initiating on either oral or
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long-acting injectable risperidone. METHODS: Retrospective analysis (Jan 2006-
Dec 2008) of Texas Medicaid data was conducted for patients  18 years old with
schizophrenia (ICD-9: 295.xx). Patients who initiated either oral (oral cohort) or
injectable risperidone (injectable cohort), had no prior risperidone for at least 12
months, and had at least one additional prescription following initiation were
included. Medical care services and costs were compared within and between co-
horts for 12months pre- and post-initiation using paired-, independent t-tests and
McNemar tests. RESULTS: 1544 patients were included (oral cohort: n1261, mean
age  38yrs, 54% male; injectable cohort: n283, mean age39yrs, 61% male). The
injectable cohort (4.6, SD2.9) had a significantly higher mean Chronic Disease
Score (CDS) compared to the oral cohort (3.2, SD2.9) (p0.05). The percent of
patients with at least one psychiatric-related hospitalization significantly de-
creased by 10.6% in the injectable cohort (25.0% to 14.5%; p0.05) compared to 6.1%
in the oral cohort (18.7% to 12.6%; p0.05), and average hospital length of stay (LOS)
was significantly reduced by 2.5 days (4.4 to 1.9 days) versus 0.9 days (2.6 to 1.7
days), respectively (p0.05). Direct mental health-related medical costs signifi-
cantly decreased by $1395 ($4968 to $3573; p0.05) in the injectable cohort com-
pared to $51 in the oral cohort ($1912 to $1861; NS) (p0.05). CONCLUSIONS: For
patients initiated on long-acting injectable risperidone, clinical utilization and eco-
nomic outcomes improved one year post-initiation, as the number hospitaliza-
tions, LOS, and total mental health-related medical costs decreased. While inject-
able cohort patients may be a sicker population (as evidenced by higher CDS and
higher levels of baseline and follow-uputilization and costs), their level of improve-
ment was higher than that of the oral cohort.
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OBJECTIVES: Previous evidence has demonstrated that the presence of psychiatric
comorbidities in patients with ADHD is associated with increased total healthcare
costs. This study examined factors associated with healthcare costs in a commer-
cially-insured population with ADHD and 1 psychiatric comorbidity.METHODS:
Using the Market Scan database (2005–2007), we examined claims for 4,613 com-
mercially-insured patients ages 6 to 17 years with a diagnosis of ADHD (ICD-9:
314.xx) and 1 of the following psychiatric comorbidities: oppositional defiant
disorder, conduct disorder, learning disability, anxiety disorder, and depression.
Percent of days covered (PDC) by 1 ADHD medication was calculated for the
12-month period following index date. The population was divided into two
groups: consistent users (PDC70%) or inconsistent users (PDC70%). Chi-square
tests for categorical variables and t-test or ANOVA for continuous variables were
employed to identify differences between the groups (significant when P0.05).
Generalized linearmodels with gamma-distributed error and log-link were used to
evaluate the association between total healthcare costs and covariates that in-
cluded patient demographics, each comorbidity, and treatment-consistency.
RESULTS: The study population was predominantly male (64.8%), had a mean age
of 12.6 years, and was predominantly urban (87.3%). In specifying the regression
model, the following covariates were significantly associated with the cost out-
come: treatment-consistency, age, gender, insurance type, index year, and each of
the tested psychiatric comorbidities. Relative to consistent users, inconsistent us-
ers had lowermodeled total healthcare costs (P0.0001). Female sex, increased age,
and each of the psychiatric comorbidities were associated with increased total
healthcare cost relative to their counterpartswithout those attributes (P0.0087 for
female sex; P0.0001 for all other covariates). CONCLUSIONS: In the studied pop-
ulation of children and adolescents with ADHD and concurrent mental health
diagnoses, after controlling for significant covariates, inconsistent use of ADHD
medications was associated with lower total healthcare costs than consistent use.
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THE COST-EFFECTIVENESS OF GUANFACINE EXTENDED RELEASE (GXR) VERSUS
ATOMOXETINE (ATX) FOR THE TREATMENT OF ATTENTION-DEFICIT/
HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
Erder M1, Chen K2, Wu EQ2, Hodgkins P1, Sikirica V1
1Shire Pharmaceuticals, Wayne, PA, USA, 2Analysis Group, Inc., Boston, MA, USA
OBJECTIVES:To evaluate the cost-effectiveness of GXR vs. ATX for the treatment of
ADHD in children and adolescents from a US third-party payer perspective.
METHODS:Aneconomicmodelwas developed to estimate the cost effectiveness of
GXR vs. ATX during a 4-week drug titration period and a 48-week maintenance
period (one-year time horizon). Effectiveness was measured by the number of re-
sponders (defined as patients with 25% reduction in ADHD-Rating Scale-IV total
observed score compared to baseline), and estimated quality-adjusted life years
(QALYs). The model assumed all patients received treatment until the end of titra-
tion and only responders continued treatment afterwards. A uniform constant
discontinuation rate, based on the long-term trials of GXR and ATX, was applied.
Response rates were obtained from a matching-adjusted indirect comparison of
efficacy between GXR and ATX based on the Phase III trials. Published utilities
corresponding to response and non-response health states were applied. Disutility
due to adverse events was applied to the entire titration period. Costs included
published drug wholesale acquisition costs (WAC) in 2010 US dollars. Incremental
cost per QALY and incremental cost per responder were estimated for GXR com-
pared to ATX. Various one-way sensitivity analyses (SA) were conducted to exam-
ine the robustness of the model. RESULTS: Despite the lower WAC unit price, GXR
had an incremental cost of $171 over ATX because more GXR patients achieved
response and continued treatment. In the base case, the cost/QALY was $24,688
and the incremental cost per responder was $1,979. Most scenarios in the one-way
SA resulted in a cost/QALY below $50,000, with the exceptions of increasing GXR or
decreasing ATX costs by 25%. CONCLUSIONS: Compared to ATX, GXR is cost-effec-
tive, at the cost that is lower than the socially acceptable willingness-to-pay
threshold of $50,000/QALY, for the treatment of ADHD in children and adolescents.
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ECONOMIC IMPLICATIONS OF THE EFFECT OF LURASIDONE VERSUS OTHER
SELECTED ATYPICAL ANTIPSYCHOTICS ON CARDIOMETABOLIC PARAMETERS
IN PATIENTS WITH SCHIZOPHRENIA
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OBJECTIVES: A cost-consequence analysis was performed to assess the economic
implications of changes in cardiometabolic parameters after six-week treatment
with lurasidone vs. other selected atypical antipsychotics in patients with
schizophrenia.METHODS:Amodel using discrete event simulationwas developed
to assess the economic impact from a US payer perspective over a two-year time-
frame. It uses baseline patient-level profiles from lurasidone trials to simulate
changes in cardiometabolic parameters (e.g., LDL, HDL, triglycerides, total choles-
terol, fasting glucose (FG), and BMI) associated with each treatment over six-weeks
using data from lurasidone clinical trials for lurasidone and olanzapine and from
the literature for risperidone, quetiapine IR and XR. Based on the simulations, the
model projects the number of cases requiring pharmacological treatment for hy-
perlipidemia (i.e., LDL130 mg/dL), hyperglycemia (i.e., FG 100-126 mg/DL), as well
as diabetes and cardiovascular events (CVD) using risk equations from the
Framingham Heart Study. Costs (in 2010 values) are accrued according to each
patient’s specific experience with treatments and events over the course of the
simulation. RESULTS: Per 1,000 treated patients, lurasidone is predicted to result in
47, 14, 16, and 2 fewer incident diabetes; 74, 56, 56, and 49 fewer hyperlipidemia
cases; and 191, 82, 82, and 16 fewer hyperglycemia cases than olanzapine, risperi-
done, quetiapine IR, and quetiapine XR, respectively. CVD events are also fewer
with lurasidone, but the differences among treatments areminimal. These clinical
benefits would result in net savings of $857, $414, $431, and $147 per patient,
respectively, and $5,803, $8,657, $9,753, and $7,647 per patient, respectively, if in-
cluding the costs of antipsychotic treatment. CONCLUSIONS: Based on the results
of these economic analyses, lurasidone represents a potentially cost-saving alter-
native for the treatment of patients with schizophrenia.
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COST-EFFECTIVENESS OF ANTIDEPRESSANT THERAPIES IN KOREA
Shin S, Jung SY, Song H, Park J, Ahn J
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OBJECTIVES: To assess cost effectiveness (CE) of antidepressant (AD) therapy, an-
tidepressantswere grouped as tricyclic antidepressants (TCAs), selective serotonin
reuptake inhibitors (SSRIs), and new antidepressants (NADs; SNRIs and others) and
a CEmodel, reflecting relationship between adherence and relapse among patients
with depression in Korea, was developed. METHODS: Effectiveness and cost pa-
rameters were estimated using the KoreanHealth Insurance Review&Assessment
Service (HIRA) claim database (2006-2008). Subjects were selected by age of 18-84,
without a prior history ofmedical visit due to depressionwithin 6-month pre-index
period and with at least 3 psychiatric visits within 3-month post-index period. A
decision-tree model comparing the three ADs groups captured rate of patient ad-
herence, rate and frequency of relapse with/without requiring hospitalization and
healthcare resource utilization associated costs. Adherence was defined as over
75% of Medication Possession Ratio (MPR) in 3-month pre-index period. Costs were
estimated with healthcare system perspective excluding unobservable out-of-
pocket payment (in 2010 KRW). Primary outcome was proportion of patients with
relapse by adherence or nonadherence. RESULTS: The adherence rate was 16.17%
in TCAs, 32.57% in SSRIs, and 34.18% in NADs. The proportions of patients experi-
encing a relapse requiring hospitalization 3.48%, 1.79%, 2.93%, for TCAs, SSRIs,
NADs while the proportion of patients with a relapse not requiring hospitalization
were 33.26%, 13.23%%, 12.59%, respectively. The expected cost of TCAs was
341,187KRW, SSRIs 415,282KRW, NADs 452,586KRW, and expected probabilities to
prevent relapse was 69.9% in TCAs, 76.6% in SSRIs, 74.8% in NADs. The result of
cost-effectiveness analysis was SSRIs is the most cost-effectiveness AD group
(ICER: 1,102,548KRW per relapse prevented). These findings were supported by
sensitivity analysisCONCLUSIONS: The use of SSRIs for treatmentwith depression
in Korean healthcare setting is predicted in this model to results in better clinical
outcomes and lower total healthcare costs over than its comparators.
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COST-EFFECTIVENESS AND BUDGET IMPACT OF ADJUNCT QUETIAPINE
FUMARATE EXTENDED-RELEASE IN PATIENTS WITH MAJOR DEPRESSIVE
DISORDER WITH AN INADEQUATE RESPONSE TO PREVIOUS THERAPY
Svedsater H1, Locklear J2, Johal S3, Stillman IO4
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OBJECTIVES:Major depressive disorder (MDD) is estimated to affect 3.4% of the US
population. The goal of MDD treatment is remission. We determined the cost-
effectiveness (CE) of adjunct quetiapine fumarate extended-release (QTP XR) ver-
sus adjunct aripiprazole ([ARP] 15 mg/d), and budget impact of adjunct QTP XR in
MDD patients with an inadequate response to previous antidepressant therapy.
METHODS: The CE model used a Markov process to model outcomes in 2nd- and
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